enfortumab vedotin
Ligand Summary
Enfortumab vedotin-ejfv is an ADC. The antibody is a human IgG1 directed against Nectin-4, an adhesion protein located on the surface of cells. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease-cleavable linker. Nonclinical data suggest that the anticancer activity of enfortumab vedotin-ejfv is due to the binding of the ADC to Nectin-4-expressing cells, followed by internalization of the ADC-Nectin-4 complex, and the release of MMAE via proteolytic cleavage. Release of MMAE disrupts the microtubule network within the cell, subsequently inducing cell cycle arrest and apoptotic cell death.
ChEMBL: CHEMBL3301589
DrugCentral: 5366
LyCHI: enfortumab vedotin
Target Activities
10 Activities
Items per page:
10
1 – 10 of 10
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
BINDING AGENT | ||||||
Ki | BINDING AGENT | |||||